CYP19A1 and breast cancer: The discovery of the off-target CYP11B2 inhibition effect of fadrozole, an approved non-steroidal cytochrome P450 19A1 (CYP19A1) inhibitor for breast cancer management, led to the development of its derivative, 5R-fadrozole (72).